• News
  • BioTech

Hollis-Eden appoints CEO

San Diego-based Hollis-Eden Pharmaceuticals Inc. (Nasdaq: HEPH) has appointed James M. Frincke as president and CEO, three months after the company dismissed its former CEO and founder Richard Hollis.

The company did not give a reason for Hollis' departure, and Frincke, Hollis-Eden's chief operating officer, stepped in as interim CEO shortly after.

"I'm excited," Frincke said. "We have a lot of work to do. We have a good compound; it's a matter of navigating this marketplace."

Frincke joined Hollis-Eden as vice president of Research and Development in 1997 and was promoted to executive vice president in 1999 and to chief scientific officer in 2001. He became chief operating officer in 2008.

Frincke joined Hollis-Eden from Prolinx Inc., where he served as vice president of Therapeutics Research and Development from 1995 to 1997.

He has worked for 28 years in the biotechnology industry, managing various drug development programs and holding several executive positions at companies including Hybritech/Eli Lilly and SyStemix Inc., which was acquired by Novartis.

Frincke received his B.S. in Chemistry and his Ph.D. in Chemistry from the University of California, Davis.

Frincke completed his postdoctoral work at the University of California, San Diego.

User Response
0 UserComments